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Abstract 
Objective: Colorectal cancer is the third most commonly reported cancer in the world and about 50% of patients are 
diagnosed over the age of 70 years. The authors discuss age-related changes in organ function, comorbidities and frailty in 
the elderly, and their impact on chemotherapy toxicity. 
Methods: The authors review data from observational studies and subgroup analyses of randomized clinical trials on 
adjuvant chemotherapy in elderly colorectal cancer patients. 
Results: Several large population-based studies suggest that adjuvant chemotherapy is offered less frequently to elderly 
patients, although in recent years the prescription patterns tended to significantly increase. In fact, data from retrospective 
analyses of randomized trials indicate that elderly stage III colorectal cancer patients may get similar clinical advantage 
from adjuvant treatment with fluoropyrimidines, although major comorbidities may substantially limit life expectancy and 
minimize the survival benefits. The use of oxaliplatin-based regimens needs to take into account the individual risk/benefit 
profile due to lack of unequivocal evidence of positive literature data. 
Conclusions: Adjuvant chemotherapy of colorectal cancer should be investigated by prospective trials specifically 
designed for the elderly. Fit elderly patients should be offered standard adjuvant treatments, while modified schedule, 
attenuated doses or even treatment omission can be offered to more frail patients. 
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Introduction 
Colorectal cancer and the elderly 
Colorectal cancer (CRC) is the second most common cause of death from cancer in both men and women in Europe and is 
the third most commonly reported cancer in the world [1]. In 2006, CRC was the second most common form of cancer 
diagnosed in Europe, with a total of 412900 new cases and 207400 deaths. In particular, stage III CRC affects 
approximately 33000 elderly patients annually in the U.S. [2]. 
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The incidence of CRC increases continuously with advancing age. Currently, the median age at diagnosis of CRC in the 
U.S. is 72 years old and approximately 50% of CRC patients are ≥70 years old [3]. As the demographic proportion of 
elderly individuals continues to grow, the medical and social burden of CRC will increase over coming years. 
The age limit currently accepted for the elderly definition is 70 years, although chronologic age is generally an imperfect 
surrogate for biological age. Ageing is associated with progressive decline of multiple organ functions, with an increased 
prevalence of comorbidity conditions. These changes influence treatment decision-making due to decrease of life 
expectancy and tolerance to chemotherapy. The best estimates of individual functional reserve may be provided by a 
comprehensive geriatric assessment (CGA), which takes into account functional and psychological status, comorbidities, 
socioeconomic conditions, pharmacy, cognition, nutrition and presence of specific geriatric syndromes. The assessment of 
function needs to include Activities of Daily Living (ADL) and Instrumental ADL (IADL) in addition to performance 
status and comorbidities indexes such as Cumulative Illness Rating Scale-Geriatrics (CIRS-G) and Charlson’s Scale [4]. 
Not surprisingly, this index was independently correlated with chemotherapy tolerance in elderly CRC patients [5]. In fact, 
comobidities can constitute the most important prognostic factor for survival and minimize the benefits of adjuvant 
treatments. According to Balducci and Extermann [6], CGA can identify three categories of older cancer patients. Group 1 
includes patients without serious comorbidity, who are functionally independent and should be treated as younger 
counterparts; they typically qualify as good candidates for clinical trials and are therefore assessed by use of Eastern 
Cooperative Oncology Group (ECOG) Performance Scale; group 2 includes frail patients, candidates for supportive care 
alone; group 3 lies in between and identify the majority of elderly patients who display a limited number of IADL 
dependences and comorbidities; they may potentially benefit from medical treatment with adequate schedules and doses, 
although each case should be assessed by a multidisciplinary team on individual basis. 
Pharmacokinetics of fluoropyrimidines and oxaliplatin in the elderly 
Age-related pharmacokinetics changes encompass decreased excretion and metabolism of drugs. Thus, agents used in 
CRC adjuvant treatment could display an increased rate of adverse events (AEs). 5-fluorouracil (5-FU) dosage is often 
reduced arbitrarily, although there is no pharmacokinetic basis for dose modification based on age alone. Published data 
give conflicting results as to whether intravenous fluoropyrimidines are more toxic in the elderly. In a metanalysis of six 
randomised clinical trials (RCTs) [7], older and poor performance status patients treated with 5-FU had higher incidence of 
non-haematological toxicity. Conversely, in the Intergroup 0089 study with adjuvant 5-FU, a secondary analysis 
demonstrated that the elderly are as likely to tolerate chemotherapy as younger patients [8]. In the metastatic setting, a 
retrospective analysis of European trials showed that fit elderly patients experience similar benefit and toxicity from  
5-FU [9]. A main determinant of this controversy depends on the use of different schedules: Infusional 5-FU displays a 
more favorable toxicity profile than bolus administration, with severe hematological toxicity seven times less  
frequent [7]. 
Capecitabine is an oral fluoropyrimidine which is metabolized to 5-FU and is generally well tolerated [10]. Thus this agent 
seems to be attractive in the elderly population due to side effects manageability and treatment compliance, with fewer 
hospital visits and no central venous catheters-related complications. The pharmacokinetics of capecitabine is not affected 
by age in patients with normal renal function, although patients with moderate renal impairment experience a higher 
incidence of severe AEs [11]. Therefore, International Society of Geriatric Oncology Chemotherapy (SIOG) taskforce 
recommends a lower starting dose in patients with creatinine clearance (CrCl) of 30-50mL/min, with absolute 
contraindication in patients with severely impaired CrCl (<30mL/min) [12]. 
Renal impairment decreases plasma ultrafiltrate platinum clearance and enhances systemic platinum exposure in cancer 
patients in cancer patients treated with oxaliplatin. However, in studies of patients with mild to moderate renal failure, no 
increased toxicities were observed. These observations are consistent with the hypothesis that the active forms of 
oxaliplatin are eliminated within the first hour after infusion by clearance mechanisms independent of renal function. 
During the later phase the inactive low-molecular-weight platinum is excreted via glomerular filtration which may explain 
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why renal impairment does not enhance oxaliplatin related toxicities; thus,  there are no data to support dose reduction 
based on chronologic age alone or renal impairment [13]. 
Literature search methodology 
The evidence regarding the tolerability and efficacy of adjuvant treatment of CRC in the elderly derives from two different 
sources: retrospective analyses of subgroups enrolled in randomized clinical trials (RCTs) without an upper age limit and 
prospective studies specifically designed to include elderly populations. For this article, the PubMed database was 
searched for articles on adjuvant chemotherapy published before January 2012; early release publications were also 
included. The search terms were ‘adjuvant’ AND ‘chemotherapy’ AND ‘colorectal cancer’ AND ‘elderly. Bibliographies 
of eligible studies’ were also reviewed to identify additional studies, while data from abstract were not included. 
Results 
Disparities of adjuvant treatment indication in the elderly 
Older patients are underrepresented in RCTs and this has led to a paucity of data available to the community oncologists to 
drive evidence-based treatment decisions; thus, treatment benefit to older patients and safety issues are often 
undetermined. 
A study of Southwest Oncology Group clinical trials active between 1993 and 1998 found that although 63% of US cancer 
patients were over 65% years old, the elderly comprised only 25% of trial participants [14]. Expanding the analysis to all 
cooperative groups and focusing on the later year (From 1997 to 2000), Lewis et al. found out that 32% of patients cancer 
trials were age 65 years or older, consisting in a larger proportion of clinical trial participants than previously reported [15]. 
Moreover, several studies have shown that older patients with stage II/III CRC receive a suboptimal adjuvant 
chemotherapy than younger ones. Possible reasons of treatment disparities include comorbidities, higher refusal rates, 
declining of functional and mental status, hospital volume and socioeconomic factors. Both physicians and patients may 
perceive a lowering of treatment efficacy and tolerance with advancing age [16]. 
In a population-based study that considered 577 CRC patients aged 65-79 and diagnosed between 1995 and 2001 in the 
Eindhoven Cancer Registry of South Netherlands, adjuvant chemotherapy administration decreased with advancing age 
(80% of patients between 65-69 versus 28% of patients aged 75-79). Nevertheless, it rose significantly over time from 
1995 (19%) to 2001 (50%), probably reflecting increasing amounts of supporting data in the literature [17]. 
The “Oregon State Cancer Registry” (OSCaR) retrospective study identified 3789 CRC patients aged ≥80 (29.5% of  
total) [18]. It was shown that octogenarians (the so called “very elderly”) received chemotherapy less frequently for every 
stage of disease, generally with single-agent. 
As to whether there has been any change in practice patterns in the past decades, the evidence is conflicting. Schrag et  
al. [19]. studied the relationship between adjuvant chemotherapy use and age in a large cohort of patients from 
population-based registries (Surveillance, Epidemiology, and End Results/Medicare-linked database) collected between 
1991 and 1996; the Authors identified 6262 stage III CRC patients aged ≥65 and highlighted an extensive use in older 
patients (78% in age group 65-69, 74% in 70-74), although treatment rates declined dramatically after 75 years (58% in 
75-79, 11% in 80-84). In this retrospective analysis, age still remained the strongest predictor of chemotherapy use after 
adjustment for confounding factors, such as comorbidities. A subsequent population-based SEER registry study on 8374 
patients failed to show any significant sign of diminishing treatment disparity according to age over the time period 
spanning 1997-2002 [20]. 
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Adjuvant treatment efficacy in the elderly: Observational studies 
An increasing amount of observational studies has addressed the question if adjuvant treatment may improve survival 
endpoints in elderly CRC patients. Two separate cohort studies from the SEER/Medicare population-based registries 
spanning the mid 90’s showed positive results. Iwashyna and Lamont [21] performed a prospective, population-based 
cohort study of 3357 elderly patients with stage III CRC. Statistical analysis demonstrated a 5-year overall survival (OS) 
improvement with 5-FU from 40.7% in untreated subjects to 52.7% in the treated population, with 27% reduction of death 
risk across 6 years of follow up and statistical significance maintained in octogenarians. In the second study from 
SEER/Medicare registries, Sunararajan et al. reported a hazard ratio (HR) of 0.66 favoring adjuvant treatment in the 
elderly [22]. 
A more recent SEER/Medicare analysis from 1997 to 2002 included 6711 stage III CRC patients aged ≥66 years. Notably, 
increasing age was inversely correlated with the use of adjuvant chemotherapy and the magnitude of treatment-related 
survival gain [23]. 
Jessup et al. [24] performed a large prospective study on the National Cancer Data Base between 1990 and 2002, including 
85934 patients with stage III CRC (Around 25% were octogenarians). Authors demonstrated that adjuvant chemotherapy 
use increased during time between 1991 (39%) to 2002 (64%), but still remained significantly lower in the elderly (80%, 
70% and 40% in patients of <70 years, 70-79 years and ≥80). Nevertheless, adjuvant treatment of older patients conferred 
a survival benefit as much as younger ones, with a 16% improvement of 5-year OS. 
Despite these evidences, it should be pointed out that observational studies cannot provide definitive demonstration that 
adjuvant therapy improves survival in the elderly, because there is not full control for the distribution of important 
covariates among treatment groups. 
On the other hand, Neogut et al. showed that nearly 30% of stage III CRC patients aged ≥65 discontinued earlier 
5-FU-based adjuvant treatment [25]. Moreover, patients receiving <5 months of treatment had mortality rates nearly twice 
higher. 
Kahn et al. reported an analysis on 705 stage III CRC patients enrolled in the CanCORS observational cohort study and 
assessed for important clinical morbid events. The Researchers showed that elderly patients aged ≥70 were treated less 
frequently with adjuvant chemotherapy (58% versus 84%), but experience similar rates of significant morbid events, even 
after adjustment for dose reduction and treatment duration [26]. 
Adjuvant treatment efficacy in the elderly: Randomized clinical trials 
The major evidence regarding adjuvant treatment of CRC might derive from two different sources: retrospective analyses 
of age subgroups enrolled into RCTs and prospective studies specifically designed for elderly. It is possible to argue that 
when clinical studies are designed to test the efficacy of a treatment intended for younger patients, only a selected 
proportion of older patients is considered for enrollment, without representation of the general elderly population. 
Moreover, the safety and efficacy of specific chemotherapy agents and combinations was not assessed in phase III RCT 
focusing primarily on the elderly. 
Fluoropyrimidines 
In 1990, bolus 5-FU became the standard adjuvant treatment for stage III CRC and the control regimen for consequent 
phase III trials, demonstrating a significant reduction of recurrence rate (41%) and mortality (33%) [27]. Sargent et al. [28] 
conducted an age-based pooled analysis of individual patient data from seven phase III RCTs which compared 5-FU plus 
leucovorin (five trials) or plus levamisole (two trials) with surgery alone in stage II/III CRC. The total enrolment cohort 
was 3351 patients, 15.1% of whom were aged ≥70. 5-FU chemotherapy conferred a 7% absolute improvement of 5-year 
OS in both younger (71% vs. 64%) and elderly patients (69% vs. 62%), while increased 5-year recurrence-free survival 
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(RFS) from 58% to 69%. No significant interaction was observed between age and treatment efficacy and safety. Age ≥70 
had no impact on recurrence risk but was prognostic for survival, as would be expected given the increased risk of dying 
from other causes. Regarding AEs, there was not higher incidence of nausea/vomiting, stomatitis or diarrhoea in the 
elderly; although leukopenia rate was significantly higher among those who received 5-FU plus levamisole, only a 
borderline increase was noted in the group treated with 5-FU and leucovorin. Octogenarians were only 0.7% of included 
patients, thus any conclusion about this age group should be drawn carefully. It should be emphasized that patients in this 
analysis were trial candidates; thus, the results can be weakened by selection bias, due to enrollment of patients with better 
performance status and minimal comorbidities as a result of screening. This could result in data with limited applicability 
to real-world patients. 
A randomized, multicenter, phase III trial compared the efficacy and toxicity of adjuvant treatment with 12 weeks 
protracted venous infusion (PVI) 5-FU versus monthly bolus 5-FU given for 6 months in stage II/III CRC [29]. The 
researchers enrolled a total of 801 patients and showed that PVI 5-FU was associated with a trend towards better RFS and 
OS compared with bolus 5-FU/LV, with significantly less toxicity. Consistent with the pooled analysis of RCTs, survival 
was similar in patients aged ≥ or <70 years. Based on these data, SIOG experts recommend infusional 5-FU as the best 
regimen in case of intravenous monotherapy, given the potential increase of toxicity with bolus regimens, particularly in 
the elderly. 
The X-ACT phase III, randomized study compared adjuvant capecitabine versus bolus 5-FU/FA in 1987 stage III CRC 
patients, with an upper age limit of 75 years and a total enrollment of 397 elderly [30]. This non-inferiority study 
demonstrated that capecitabine conferred a DFS advantage at least equivalent to Mayo Clinic regimen (In the 
intention-to-treat analysis, P< 0.001 for the comparison of the upper limit of the HR with the non-inferiority margin of 
1.20), with a superiority of RFS (HR, 0.86; 95% CI, 0.74 to 0.99; P=0.04). Aged subgroup analysis confirmed these 
efficacy results in patients aged < and ≥70 years. A more recent 5-year update from this trial showed a trend towards 
superiority of capecitabine for 5-year OS (HR, 0.86; 95% CI, 0.74-1.01; P=0.06). Nevertheless, age was an independent 
poor prognostic factor for OS in the multivariate analysis [31]. Capecitabine demonstrated a favorable safety profile also in 
older patients, who experienced significantly less diarrhoea, stomatitis, nausea, vomiting, alopecia and neutropenia, 
although more reported grade 3 hand-foot syndrome. 
Oxaliplatin-based regimens 
The Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer 
(MOSAIC) trial and the National Surgical Adjuvant Breast and Bowel Project (NSABP) C-07 trial demonstrated that 
adding oxaliplatin to a biweekly schedule of infused (MOSAIC) or weekly bolus (C-07) 5-FU/FA significantly prolongs 
DFS in stage II/III CRC, with relative risk reductions of 23% and 21%, respectively. 
The MOSAIC trial [32] was a phase III, multicenter, randomized study whose primary endpoint was the demonstration of a 
25% decrease of recurrence risk at 3 years among 2246 patients with stage II/III CRC receiving infusional 5-FU/FA alone 
(De Gramont regimen) or an oxaliplatin-based combination (FOLFOX-4). Adding oxaliplatin to 5-FU infusion and 
leucovorin significantly improved 3-year DFS from 72.9% to 78.2%. In 2009 updated data in terms of DFS and OS were 
published: 5-year DFS was 73.3 % in FOLFOX-4 group and 67.4% in 5-FU/FA group (HR, 0.80; 95% CI, 0.68 to 0.93; 
P=0.003); 6-year OS was 78.5% and 76%, respectively (HR, 0.84; 95% CI, 0.71 to 1.00; P=0.046; considering stage III 
patients subgroup: HR, 0.80; 95% CI, 0.65 to 0.97; P=0.023). No differences in DFS and OS were found in stage II; 
although a trend towards improved 5-years DFS was observed in the subgroup of patients with high-risk node-negative 
disease [33]. 
In the MOSAIC trial, median age 61 years and 463 patients were aged ≥65 (35.6% in FOLFOX-4 arm, 33.8% in 5-FU/FA 
arm). An age subgroup analysis showed that the efficacy of FOLFOX-4 vs. 5-FU/FA in terms of OS was not maintained in 
patients older than 65 years [32]. Older patients probably received short-term DFS benefit from FOLFOX-4 that 
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disappeared with longer follow-up, due to deaths from competing causes. Researchers found no difference in dose 
intensity between older and younger patients, although 5% fewer elderly patients completed the scheduled 12 courses of 
chemotherapy. 
Pooled data analysis of 3742 CRC patients from 4 RCTs testing FOLFOX-4 as adjuvant, first-line or second-line setting 
led to collection of efficacy and safety data in the elderly population (16%) [34]. It was stated that grade ≥ 3hematologic 
toxicity (neutropenia and thrombocytopenia) and fatigue were significantly higher in age group ≥70 years. Nevertheless, 
there were not age-related differences in nausea/vomiting, diarrhoea, severe neurotoxicity and overall incidence of severe 
AEs. However, we previously pointed out that elderly patients enrolled into clinical trials fulfill strict inclusion criteria and 
are obviously selected for their “fitness” and absence of severe comorbidities. Thus, some older CRC patients may not 
benefit and tolerate aggressive adjuvant treatment with newer drugs, beyond 5-FU/FA, particularly regarding 
oxaliplatin-based combinations. 
McCleary et al. [35] presented data from the ACCENT (Adjuvant Colon Cancer End Points) database on 2170 CRC patients 
aged ≥70 and treated in 6 phase III adjuvant RCTs (MOSAIC, NSABP C-07, CALGB 89803, PETACC 03, X-ACT, and 
NSABP C-06). The investigators compared 5-FU monotherapy to oral fluoropyrimidines or to combination regimens with 
irinotecan/oxaliplatin. This retrospective metanalysis found that elderly patients did not receive a clear benefit from 
combination chemotherapy and newer adjuvant regimens in terms of DFS and OS. Even considering the lack of efficacy of 
irinotecan-based therapy and looking at the 2 oxaliplatin-based trials (C-07 and MOSAIC), these results was confirmed 
(HR, 1.04 for DFS, 1.19 for OS). Recently, a subgroup analysis of the “true” elderly patients aged ≥70 years (n=315) in the 
MOSAIC trial was reported, reviewing clinical characteristics and comorbidities. It was stated that HR for DFS was 0.91 
(95% CI, 0.62 to 1.34) and HR for OS was 1.10 (95% CI, 0.73 to 1.65). The Authors declared that DFS benefit of 
oxaliplatin-based adjuvant treatment was of less magnitude in the elderly. Lack of OS differences did not seem to be 
related to comorbidities, but possibly to different management/outcome of relapses or incidence of second cancers [36]. 
The NO16968 trial (XELOXA) was an open-label, randomized, phase III study of XELOX (Oral capecitabine plus 
intravenous oxaliplatin) versus bolus 5-FU/FA as 6-months adjuvant therapy for stage III CRC [37]. The primary end point 
of the study, which enrolled 1886 patients, was to demonstrate the superiority of XELOX over 5-FU/FA in terms of DFS; 
secondary endpoints included OS, RFS, safety profiles and perceived treatment convenience. Patients in the XELOX 
group displayed significantly better outcome compared to those receiving 5-FU/FA (3-year DFS 70.8% vs. 66.5% and 
5-year DFS 66.1% vs. 59.8% (HR, 0.8; 95% CI, 0.69 to 0.93; P=0.0045). Although overall survival data are currently 
immature and longer follow up is needed, 5-year OS for XELOX and 5-FU/FA was 77.6% and 74.2%, respectively (HR, 
0.87; 95% CI, 0.72-1.05; P=0.1486). 
Regarding severe AEs, XELOX caused less stomatitis, neutropenia and febrile neutropenia than 5-FU/FA, but more 
frequent hand-foot syndrome and thrombocytopenia. Sixty-day all-cause mortality was 1% on both arms. Authors 
concluded that XELOX is feasible in the adjuvant setting and compares favorably with FOLFOX-4 in terms of toxicity. 
An age subgroup analysis showed that the 3-year DFS benefit for patients receiving XELOX versus 5-FU/FA was 
maintained in elderly patients [38]. In patients aged ≥70 years (n=409), DFS was 66% in the XELOX arm versus 60% in the 
5-FU/FA arm (HR 0.87; 95% CI 0.63 to 1.18). In patients aged ≥65 years (n=744), the respective results were 68% and 
62% (HR 0.81; 95% CI 0.64 to 1.03). However, neither result was statistically significant as the 95% CI of the hazard 
ratios crossed 1. Although overall survival data are immature, the analysis demonstrated a trend towards OS superiority for 
XELOX over 5-FU/FA in patients aged ≥65 (73% versus 70%) and ≥70 (69% vs. 67%; HR, 0.94; 95% CI, 0.66 to 1.34). 
Overall, these findings may differ from those of the MOSAIC study and the ACCENT analysis. However, it must be 
pointed out that dose intensity and treatment duration were significantly lower in patients older than 70 years. In XELOX 
arm, incidence of severe AEs differed significantly in younger versus elderly patients (57% vs. 70%), particularly 
regarding grade 3/4 diarrhoea (18% vs. 26%) [39]. Based on these data, XELOX is currently considered a promising 
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regimen for adjuvant treatment of fit elderly patients with stage III CRC, although not yet included in SIOG expert 
recommendations. 
In a recent cohort U.S. study examining 2560 patients, it was stated that older age was significantly associated with 
omission of oxaliplatin in postoperative chemotherapy and treatment duration <3 months [40]. When oxaliplatin was added 
to capecitabine, a two-fold increased likelihood of treatment discontuinuation was observed, probably due to toxicity. In 
fact, a randomized phase III trial comparing XELOX versus FOLFOX-4 in the metastatic setting reported a higher rate of 
severe gastrointestinal toxicity and hand-foot syndrome with the use of capecitabine [41]. 
Conclusions and future directions 
Standard adjuvant treatment of CRC in elderly patients is a controversial topic because of the lack of specific prospective 
data. The existing evidence suggests that elderly stage III CRC patients get similar clinical benefit from adjuvant 
treatment, although the advantages deriving from oxaliplatin-based regimens is less than younger patients. Moreover, the 
toxicity exacerbation (Particularly with newer oxaliplatin-based combinations) still constitutes the major issue. Careful 
monitoring for AEs and rapid intervention with supportive measures when toxicity occurs is a mandatory component of 
optimal care. Taking in mind that age alone should not drive clinical decision-making, elderly patients should be evaluated 
for adjuvant treatment on an individual basis and by a multidisciplinary team through a CGA. When chemotherapy is 
medically appropriate, patient preferences need to be weighed, along with individual functional reserve and life 
expectancy. It is important to establish an overall treatment plan for the management of elderly CRC patients, even if the 
major issue is to effectively select patients suitable for standard or attenuated therapy. Fit elderly patients should be offered 
standard adjuvant treatments, although the use of oxaliplatin needs to take into account the individual risk/benefit profile 
in presence of controversial literature data. Survival benefit may be important for some patients, and toxicity is 
manageable with attention to the increased risk of myelosuppression in the elderly. Less toxic options or even treatment 
omission can be offered to more frail patients. 
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